Century Therapeutics, Inc. Debt Instrument, Increase (Decrease), Net
Century Therapeutics, Inc. (IPSC) reported Debt Instrument, Increase (Decrease), Net of $1.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet · last filed 2026-08-12
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for the quarter ending 2026-06-30 was $105.00K.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for the quarter ending 2026-03-31 was $1.37M.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for the quarter ending 2023-06-30 was $270.00K.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for the quarter ending 2023-03-31 was $855.00K.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for fiscal 2024 was $1.25M, a 20.13% decline from fiscal 2023.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for fiscal 2023 was $1.57M.
- Century Therapeutics, Inc. debt instrument, increase (decrease), net for fiscal 2021 was $0.00.
| Period end | Debt Instrument, Increase (Decrease), Net 3 month | Debt Instrument, Increase (Decrease), Net 6 month | Debt Instrument, Increase (Decrease), Net 12 month |
|---|---|---|---|
| 2026-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.48M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $1.37M 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $393.00K 10-Q · filed 2026-08-12 | ||
| 2024-12-31 | $1.25M 10-K · filed 2026-03-12 | ||
| 2023-12-31 | $1.57M 10-K · filed 2024-03-14 | ||
| 2023-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.13M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $855.00K 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $0.00 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |